Lunit, a leader in AI-powered cancer diagnosis and treatment tools, has announced a major rebranding. The company is now operating under the Lunit name, integrating its various services and brands into a single global identity. This move aims to connect their work across breast health, AI detection, and personalized cancer therapies under one unified brand.

Building a Complete Cancer Detection Ecosystem

The rebranding involves incorporating Volpara Health Technologies into Lunit’s broader platform. This integration creates a comprehensive system covering risk assessment, early detection, imaging quality, and precision medicine. By combining these areas, Lunit is now among the few companies in healthcare with a full-spectrum AI portfolio for cancer care, from screening to targeted treatment.

This expanded ecosystem is designed to provide greater value for healthcare providers, researchers, and patients around the world. Lunit’s solutions help improve the accuracy of cancer detection and offer more personalized treatment options, making a real difference in patient outcomes.

Expanding Global Reach and Streamlining Operations

To support faster regional growth, Lunit has reorganized its global operations under a unified structure. A new division, Lunit International, will lead business development and customer engagement efforts across key regions like the U.S., Europe, Asia, and Oceania. This move is intended to make the company more agile and responsive to regional needs.

As part of this transition, Lunit has launched a new website, reflecting its updated digital identity. The website serves as a central hub where clinicians, researchers, and partners can access information about Lunit’s AI solutions, research initiatives, and corporate updates.

Despite the rebranding, Lunit’s core mission remains unchanged: to make AI the standard in all stages of the cancer journey. The company is committed to ensuring that advanced diagnostics are accessible worldwide, regardless of location or available resources.

Brandon Suh, Lunit’s CEO, expressed optimism about the future, saying, “This marks the start of a new era of collaboration and impact across every stage of cancer care.” The integration of Volpara is a significant step toward conquering cancer through innovative AI tools. By unifying its brand and expanding its ecosystem, Lunit aims to revolutionize how cancer is detected and treated globally.

Inspired by

• https://ai-techpark.com/volpara-now-operates-under-lunit-brand/